Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia

Efrosyni Apostolidou, Elihu Estey, Jorge Cortes, Guillermo Garcia-Manero, Stefan Faderl, Deborah Thomas, Apostolia Tsimberidou, Hagop Kantarjian, Francis J. Giles*

*Corresponding author for this work

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

In a recent phase I study, a combination of gemcitabine at 10mg/(m2min) for 12h and mitoxantrone 12mg/m2 daily for 3 days, achieved a complete remission (CR) in 3 of 12 (25%) patients with refractory leukemia. A pilot assessment of this regimen was conducted to determine its tolerability in patients with refractory acute myeloid leukemia (AML). In a cohort of 18 patients with very refractory disease (6 primary refractory, 12 relapsed, mean initial CR duration 3.5 months), one patient achieved a CR, a second CR with incomplete platelet recovery (CRp). Sepsis and mucositis were significant extramedullary toxicities. The gemcitabine and mitoxantrone regimen was feasible to administer even in heavily pre-treated patients. It was not active in patients who had failed a prior salvage regimen. It may warrant further study in patients with primary resistant AML.

Original languageEnglish (US)
Pages (from-to)301-304
Number of pages4
JournalLeukemia Research
Volume27
Issue number4
DOIs
StatePublished - Apr 1 2003

Keywords

  • Gemcitabine infusion
  • Mitoxantrone
  • Refractory myeloid leukemia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia'. Together they form a unique fingerprint.

Cite this